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ABSTRACT
Objectives To review the scientific evidence base on 
antimicrobial use (AMU) and antimicrobial resistance 
(AMR) in human and animal sectors in the Lao PDR 
(Laos).
Methods We reviewed all publications from July 1994 
(the first article describing AMR in Laos) to December 
2020. Electronic searches were conducted using Google 
Scholar and PubMed with specific terms relating to AMR 
and AMU in Lao, French and English languages.
Findings We screened 1,357 peer- reviewed and grey 
reports by title and abstract and then full articles/reports. 
Of 80 included, 66 (83%) related to human health, nine 
(11%) to animal health, four (5%) to both animal and 
human health and one (1%) to the environment. Sixty- 
two (78%) were on AMR and 18 (22%) on AMU. Extended 
spectrum beta lactamase- producing Escherichia coli was 
the greatest concern identified; the proportion of isolates 
increased fivefold from 2004 to 2016 (2/28 (7%) to 27/78 
(35%)) from blood cultures submitted to the Microbiology 
Laboratory, Mahosot Hospital, Vientiane. Carbapenem 
resistant Escherichia coli was first identified in 2015. 
Methicillin- resistant Staphylococcus aureus (MRSA) was 
uncommon, with 15 cases of MRSA from blood cultures 
between its first identification in 2017 and December 
2020. AMR patterns of global antimicrobial resistance 
surveillance system (GLASS) target pathogens from 
livestock were less well documented. There were few data 
on AMU in human health and none on AMU in livestock. 
The first hospital AMU survey in Laos showed that 70% 
(1,386/1,981) of in- patients in five hospitals from 2017 to 
2018 received antimicrobial(s). Antibiotic self- medication 
was common.
Conclusion AMR in Laos is occurring at relatively 
low proportions for some GLASS pathogens, giving 
the country a window of opportunity to act quickly to 
implement strategies to protect the population from 
a worsening situation. Urgent interventions to roll out 
new guidelines with enhanced one- health antibiotic 
stewardship, reduce antibiotic use without prescriptions, 
enhance surveillance and improve understanding of AMU 
and AMR are needed.
BACKGROUND
Antimicrobial resistance (AMR) is of major 
global public health concern, increasing 
in frequency for key pathogens and key 
Key questions
What is already known?
 ► Irrational use of antimicrobials driving antimicrobial re-
sistance (AMR) is a critically important issue worldwide.
 ► Data on antimicrobial susceptibility patterns of the 
global AMR surveillance system pathogens are com-
monly available in wealthier countries but fewer 
data are available in low- income and middle- income 
countries.
 ► There are scattered reports of AMR and antimicrobi-
al use (AMU) in Laos, but they have not been synthe-
sised to inform policy and implementation.
What are the new findings?
 ► Extended spectrum beta lactamase- producing 
Escherichia coli has become the greatest AMR concern 
in Laos.
 ► Carbapenem resistant E. coli and Klebsiella pneumo-
niae have been reported recently. Colistin resistant E. 
coli and K. pneumoniae have been reported in both 
livestock and a healthy individual.
 ► Data suggest a high proportion of hospital AMU in hu-
man health but no AMU data in animal health were 
found.
What do the new findings imply?
 ► The AMR situation in Laos is not as severe as in 
surrounding countries, suggesting that Lao has the 
opportunity to act quickly to control and combat AMR 
to avert a worsening situation.
 ► There is an urgent need for AMR and AMU monitoring in 
both hospitals and the community, improved antibiotic 
stewardship in humans and livestock and enhanced 
control of antibiotic use without prescriptions.
 ► More research is required to investigate appropriate 
solutions for the Lao context.
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antimicrobials. Evidence suggests that this is accelerated 
by antimicrobial use (AMU). AMR results in both direct 
consequences, such as longer duration of illness and 
hospital stay, and increased morbidity/mortality, and indi-
rect consequences such as reduced productivity caused 
by sickness and increased family, community and health 
system economic burden.1 2 Since 2000, the number of 
antibiotics under development has fallen sharply.3 It has 
been estimated that approximately 700,000 people die 
every year from resistant pathogens, including bacterial 
infections, tuberculosis (TB), HIV and malaria.4 If AMR 
continues to increase with no appropriate action being 
taken, this could contribute 10 million excess deaths by 
2050.4
Laos is a low- and middle- income country, bordered 
by Thailand, Cambodia, Vietnam, China and Myanmar. 
National action plans on AMR are available in all these 
countries, and Laos, and most of surrounding countries 
(except China and Vietnam) participate in the global 
antimicrobial resistance surveillance system (GLASS).5 
However, in Laos, as is common elsewhere, different 
sectors (healthcare, agriculture, drug regulatory authori-
ties) tend to work on their own strategies with little inter-
action. In October 2016, the Global Antibiotic Resistance 
Partnership- Laos committee was established as a Ministry 
of Health (MoH) technical working group to review the 
scientific evidence base to inform efforts to combat AMR 
in Laos, and provide evidence to the MoH AMR Surveil-
lance and Control Committee. This report summarises 
the evidence base on AMU and bacterial resistance 
patterns in humans, animals and the environment in 
Laos, to identify important gaps and discusses the impli-
cations for health policy.
METHODS
Information sources and inclusion/exclusion criteria
This narrative review focuses on the existing evidence on 
the prevalence of antimicrobial resistance among bacte-
rial pathogens, particularly GLASS target pathogens, 
Mycobacterium tuberculosis and other available AMR path-
ogens in humans, animals and the environment in Laos. 
The review also describes data on AMU in these three 
sectors. All the peer- reviewed and grey literatures relating 
to Lao AMU and AMR data in humans, animals and the 
environment from 1994 (the year of the first published 
article on AMR in Laos) to 31 December 2020 in Lao, 
French and English languages were screened by title 
and abstract. We also included epidemiological studies, 
case studies and available raw data/reports from various 
governmental and non- governmental sectors in Laos.
This review does not include peer- reviewed or grey 
literatures relating to antimalarial, antiprotozoal, antihel-
mintic, antifungal and antiviral resistance.
Published literature
Electronic searches were conducted using Google 
Scholar and PubMed. The search terms used were ‘Laos, 
Lao, antimicrobial susceptibility, antimicrobial resist-
ance, antimicrobial use, animals, pharmacy, prescrip-
tion, prevention, self- medication, environment, Escher-
ichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, 
Staphylococcus aureus, Streptococcus pneumoniae, Salmonella 
spp, Shigella spp, Neisseria gonorrhoeae, Salmonella enterica 
serovar Typhi, Salmonella Paratyphi, Vibrio cholerae, Myco-
bacterium tuberculosis, extended spectrum beta lactamase 
(ESBL) and methicillin- resistant Staphylococcus aureus 
(MRSA)’. Eligible articles were included after reading 
the abstracts. Full articles were then reviewed to obtain 
relevant data for inclusion.
Grey literature
Relevant Lao Government departments were visited and 
data and reports requested. Annual reports, student 
project theses, results of projects on antibiotic use and 
resistance in Laos were requested from the Lao Food and 
Drug Department, Department of Healthcare and Reha-
bilitation, National Tuberculosis Centre, Microbiology 
Laboratory of Mahosot Hospital (the largest central 
hospital in Laos- the majority of laboratory data in this 
review were from this laboratory, which acts as a reference 
microbiology laboratory and provides services across the 
country), Livestock and Fisheries Department of Ministry 
of Agriculture & Forestry, Faculty of Agriculture of Lao 
National University and Institut de la Francophonie pour 
la Médecine Tropicale (IFMT).
We did not grade the quality of evidence, nor contact 
the authors for more information. The review results 
were described without further analysis.
Patient and public involvement
There was no patient or public involvement in the plan-
ning or conduct of this work.
FINDINGS
From 28 July 1994 to 31 December 2020, 1,357 peer- 
reviewed and grey literature reports were identified 
and screened by title and abstract; 487 (36%) were peer 
reviews from electronic searches and 870 (64%) were 
datasets or grey literature. After review, 80 peer- reviewed 
and grey literature reports were included. Of these, 62 
(78%) were related to AMR and 18 (22%) to AMU in 
Laos (figures 1 and 2).
Of 80 data sources, 66 (83%) related to human health 
only, 9 (11%) related to animal health, 4 (5%) covered 
both human and animal health and one (1%) related to 
environmental AMR pathogens (online supplemental 
appendices 1–4). Forty- one (51%) were from, or related 
to, work done by the Lao- Oxford- Mahosot Hospital- 
Wellcome Trust Research Unit (LOMWRU), Mahosot 
Hospital, Vientiane.
Antimicrobial susceptibility testing (AST) described in 
this review was based on the clinical and laboratory stan-
dard institute (CLSI) methods, as was used in all microbi-
ology laboratories in Laos until recently. It was replaced 
by the European Committee on AST system in mid- 2019.6
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Evidence for AMR in bacteria infecting humans in Laos
From 1994 to 2020, S. aureus, E. coli, K. pneumoniae and 
S. Typhi were the most frequently mentioned bacterial 
pathogens in literature from Laos, mostly from fever aeti-
ology studies with multiple pathogens isolated.
No distinction is made here between community- 
acquired infections (CAI) and hospital- acquired infec-
tions (HAI)7 as most available data sources did not 
include this information. The largest available dataset in 
this review was from Mahosot Hospital from 2000 to 2016, 
which did not include information to be able to identify 
HAI reliably. However, among 37,443 patients with blood 
cultures submitted to this laboratory during this period, 
blood cultures from 32,675 (87%) were submitted within 
48 hours after admission to hospital; which are therefore 
believed to represent CAI. Blood cultures from 4,396 
(12%) patients were submitted after 48 hours of admis-
sion. However, we cannot be sure that these represent 
HAI because of delays in submitting blood cultures, that 
only became an accessible service in 2000. In addition, 
372 (1%) of patient records lacked dates of admission 
and/or blood cultures. It will be vital to systematically 
collect such data to increase our understanding of the 
comparative antimicrobial susceptibility patterns of both 
CAI and HAI.8
AMR of WHO GLASS target pathogens
Escherichia coli
ESBL- producing E. coli were first identified in Laos in 
2004 from blood.9 Chang et al. reported the trend of 
ESBL- producing E. coli bacteraemia in Laos from 2010 to 
2014, increasing from 7.8% (4/51) to 34.7% (17/49).10 
A larger dataset from Microbiology/LOMWRU labora-
tory from 2004 to 2016, which included data from Chang 
et al., showed that the actual proportion increased five- 
fold from 7% (2/28) in 2004 to 35% (27/78) in 2016 
(figure 3).8 Among 280/1,837 inpatients and outpa-
tients at Mahosot Hospital with urinary tract infection 
(UTI) that yielded significant growth from 2010 to 2011, 
194/280 (69%) grew E. coli. Of these, 28/194 (14%) 
were confirmed as ESBL- producing. Only 22/151 (15%) 
were resistant to nitrofurantoin,11 which is not yet avail-
able in Laos. More recent (2017–2018) data on urine 
cultures from patients with UTI from Mahosot Hospital 
included 169 E. coli isolates, of which 90 (53%) were 
ESBL- producers, and 43 (25%) were multidrug resistant 
(MDR—non- susceptible to ≥1 agent in ≥3 antimicrobial 
categories).12 Nitrofurantoin resistance was found in 5% 
(8/169).13 E. coli carbapenem resistance was first identi-
fied in Laos in 2015 from a pus specimen from a Mahosot 
Hospital inpatient. By December 2020, nine more 
carbapenem resistant isolates from hospitalised patients 
had been identified by the Microbiology/LOMWRU 
laboratory (two from blood).13–15 New Delhi Metallo- 
betalactamase (NDM) genes were identified from four.14
Klebsiella pneumoniae
ESBL- producing K. pneumoniae were first identified in 
Laos from blood in 2000. Of 284 K. pneumoniae isolates 
from blood cultures at Mahosot Hospital from 2000 to 
2016, 39 (14%) were ESBL producers and 20/39 (51%) 
were also MDR.12 Unlike ESBL- producing E. coli, ESBL- 
producing K. pneumoniae showed no clear time trend over 
this period and the proportion varied from 3% to 41% 
(online supplemental appendix 5).8 10 Of 32 K. pneumo-
niae isolates from blood during 2015 and 2016, 18 (56%) 
carried the CTX- M- 15 gene.16 K. pneumoniae carbapenem 
susceptibility has been tested since 2010. Five resistant 
isolates were reported from non- blood specimens and 
one from blood between January 2018 and December 
2020. Of these six, only three isolates were tested for 
carbapenemase and all of them carried NDM genes.13
ESBL-producing Enterobacterales carriage/colonisation and 
colistin resistance studies
ESBL- producing Enterobacterales stool colonisation has 
been investigated in Lao communities. ESBL- producing 
E. coli were found in 25% (100/397) of young children in 
12 preschool childcare facilities in the capital city and the 
wider province of Vientiane.17 Of stool specimens from 
57 healthy adults in southern Laos, 41 (72%) contained 
Figure 1 Search strategy and selection of studies for the 
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ESBL- producing E. coli.18 In a larger community cross- 
sectional study in a remote village in north- east Laos in 
2016, ESBL- producing E. coli colonisation was found in 4% 
(11/268) of rectal specimens from healthy individuals.19 
The most recent study published in 2021 demonstrated 
that 174/236 (74%) stool specimens collected from 20 
healthy European visitors contained ESBL- producing 
Gram- negative bacteria during their stay in Laos. Of 292 
ESBL- producing Gram- negative isolates from stool speci-
mens, the CTX- M- 15 gene was most frequently identified 
(262/292 (77%)).20
Although colistin is not available for human use in Laos, 
it is used for livestock.21 Eleven (6%) colistin resistant K. 
pneumoniae isolates were reported from 190 stool samples 
of healthy Lao individuals. Among these 11 isolates, nine 
different STs were reported and seven (64%) had mgrB 
genes without mutations.22 Of three isolates from Olaitan 
et al.,22 all three carried mcr-3 variants, and one carried 
both mcr-3 and mcr-8.23
Staphylococcus aureus
The first isolation of MRSA (mecA positive) in Laos was 
reported in 1997 from the nose of an inpatient, without 
signs of local infection, in a central Vientiane hospital.24 In 
2002, the first two MRSA isolates from clinically infected 
patients were reported.25 The first MRSA isolated from 
blood was identified at Mahosot Hospital in 2017, with 14 
subsequent cases by December 2020 for the whole country. 
S. aureus from non- blood culture specimens during 2012 
and 2014 was described in 2017 with Panton- Valentine 
leukocidin positivity reported in 56/96 (58%) of isolates. 
MRSA was found in seven (7%) isolates including impor-
tant strains circulating in neighbouring countries, such 
as ST239- MRSA- III and ST59/952- MRSA- V(T).26 More 
recent data during 2017 and 2018, yielded 95/619 (15%) 
MRSA from non- blood culture specimens submitted to 
Figure 2 Distribution of antimicrobial resistance (AMR), left and antimicrobial use (AMU) data sources, right, in this review. 
Numbers after each province name (in parentheses) refer to the number of studies relating to either AMR or AMU in Laos. 
Numbers in parentheses were counted based on number of studies/reports relating to that province. Thirteen and two data 
sources were not included in the AMR and AMU maps, respectively, because their study sites were not clearly specified.
Figure 3 Trends of Escherichia coli, ESBL E. coli and MDR 
E. coli isolates from blood cultures from 2000 to 2016 at 
Mahosot Hospital, Vientiane. ESBL, extended spectrum beta 
lactamase; MDR, multidrug resistant.
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the Microbiology/LOMWRU laboratory; 7/93 (8%) were 
resistant to trimethoprim- sulfamethoxazole, 10/90 (11%) 
to ciprofloxacin, 15/91 (16%) to chloramphenicol, 19/95 
(20%) to gentamicin and 80/94 (85%) to tetracycline. No 
molecular investigations have been performed. All isolates 
were fully susceptible to vancomycin but this is not currently 
available in Laos.13
Salmonella Typhi
A case series of 913 S. Typhibacteraemic patients from 
Mahosot Hospital (2000–2018) included susceptibility data 
from diverse fever studies27–32; only 12/854 isolates (1.4%) 
were resistant to quinolones (either ciprofloxacin or nali-
dixic acid or both), 71/893 (8%) to ampicillin, 70/865 
(8%) to chloramphenicol, 67/885 (7.6%) to trimethoprim–
sulfamethoxazole and 59/848 (7%) were MDR. Ceftriaxone 
is the first choice of complicated typhoid treatment in Laos, 
and 91% (739/815) S. Typhi were highly susceptible to ceftri-
axone. There has been no report of ceftriaxone resistant S. 
Typhi since 2009.33 Fluoroquinolone resistant S. Typhi in 
Laos are rare and treatment with fluoroquinolones are still 
likely to remain efficacious, as demonstrated in a clinical trial 
from 2002.32 Azithromycin is not routinely tested against S. 
Typhi in Laos. Azithromycin minimum inhibitory concen-
tration (MIC) of ≤16 µg/mL was widely described as statisti-
cally clinical response for uncomplicated S. Typhi infection, 
232/1,460 S. Typhi isolates from Laos were described in 
Parry et al. Of 1,460 isolates, 99.5% showed MIC of  ≤16 µg/
mL.34
Non-typhoidal Salmonella
Antimicrobial susceptibility of non- typhoidal Salmonella 
spp. (NTS) has not been documented in detail in Laos. 
Between 2000 and 2012, 168 NTS (63 from blood and 105 
from faecal specimens) were isolated at Mahosot Hospital. 
NTS isolated from faecal samples were more frequently 
resistant to ampicillin and trimethoprim–sulfameth-
oxazole than those isolated from blood (p<0.05). In 
contrast, NTS resistant to ciprofloxacin were found more 
frequently in blood than in stool (p<0.001).35 In 2017, of 
519 stool cultures reported from Mahosot Hospital, 35 
grew NTS. Of these, 29% were resistant to azithromycin, 
26% to trimethoprim- sulfamethoxazole, 23% to cipro-
floxacin, 23% to ceftriaxone, 20% to chloramphenicol, 
9% to ampicillin and 6% to nalidixic acid.13
Shigella spp.
Shigella spp. infection is also not well documented in 
Laos, with only two published reports.36 37 Forty- five 
Shigella isolates from Lao patient stools during 2006 and 
2012, comprised 35 S. flexneri, nine S. sonnei and one S. 
boydii; and 14/45 (31%) were resistant to nalidixic acid 
and 34/45 (76%) were MDR. All isolates were susceptible 
to ceftriaxone and azithromycin.37
Neisseria gonorrhoeae
Four studies of Neisseria gonorrhoeae susceptibility in Laos 
have been published38–41 during this review period. In 
2003, 1/131 (0.8%) N. gonorrhoeae isolates from 1937 
genital clinical specimens was reported to be resistant to 
ceftriaxone, along with one further (0.8%) isolate with 
decreased spectinomycin susceptibility.38 Although no 
such strains have been described in subsequent studies, 
high frequencies of resistance to tetracycline, penicillin 
and ciprofloxacin were reported.39–41 More recent data 
from 2011 to 2015 included 158 N. gonorrhoeae isolated 
from 12 281 genital samples from patients at Mahosot 
Hospital; all were susceptible to ceftriaxone and spectin-
omycin. However, 99%, 90% and 85% were resistant to 
tetracycline, penicillin and ciprofloxacin, respectively.41 
N. gonorrhoeae azithromycin susceptibility has not been 
tested for in Laos.
Streptococcus pneumoniae
Two publications have described Streptococcus pneumoniae 
infections in Laos,42 43 mainly focused on central nervous 
system infections, using overlapping datasets from 
Mahosot Hospital. Moore et al. described 2/23 isolates 
of S. pneumoniae from 2003 to 2009 from blood and 
cerebrospinal fluid (CSF), with reduced susceptibility 
to penicillin (both had minimum inhibitory concen-
trations≥0.12 µg/mL (0.39 and 0.125 µg/mL, respec-
tively)).42 A larger dataset from 2003 to 2011 from the 
same hospital revealed that 3/11 isolates of S. pneumoniae 
from CSF had reduced susceptibility to penicillin.43
Acinetobacter baumannii
The first report on the susceptibility of A. baumannii in 
Laos was in 2019, describing 22 carbapenem- resistant 
A. baumannii isolates from 2017 (19 from endotracheal 
aspirates, two wound swabs and one blood culture). Of 
these, 18 (82%) were susceptible to amikacin but all were 
resistant to imipenem, ceftazidime, ciprofloxacin and 
tetracycline.14 15
Mycobacterium tuberculosis
The first multi- centre study of Mycobacterium tuberculosis 
susceptibility was conducted in 2010 in three Lao prov-
inces. Of 87 (84%) M. tuberculosis cultured from 104 
sputum samples, 8 (9.2%) were resistant to one or more 
antituberculous agents, of which seven were monore-
sistant to isoniazid (INH) and one was MDR that was 
subsequently found to be extensively drug resistant TB.44 
Somphavong et al. characterised the genetics of these M. 
tuberculosis isolates from the national survey conducted 
from July 2010 to December 2011. Of 202 isolates, the 
East African- Indian lineage was the most common iden-
tified in all provinces, except Xiengkhuang. The Beijing 
lineage was found mostly in the northern and central 
Laos.45
From 2016 to 2017, of 1,006 sputum samples submitted 
to 42 TB laboratories throughout the country, 946 (94%) 
were GeneXpert MTB/RIF positive (897 (95%) new 
cases and 49 (5%) previously treated cases). Of these, 
820 (87%) samples were available for AST. Seventy 
(8.5%) were resistant to antituberculous agents used for 
first- line treatment (either INH, rifampicin, ethambutol 
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or streptomycin). Rifampicin resistance was found in 
11/897 (1.2%) new cases and 2/49 (4%) previously 
treated cases. Five (0.6% of 820 isolates) were MDR 
(4/776 in new cases and 1/44 previously treated cases). 
No second- line TB drug (kanamycin, capreomycin and 
ofloxacin) resistance was reported.46
AMR of other bacteria of local and regional importance
Diverse other infectious diseases are common in Laos,47 
but there are very limited AMR data available. Intrinsic 
AMR is important for melioidosis and rickettsial diseases, 
reducing the spectrum of efficacious antibiotic therapy. 
Burkholderia pseudomallei is a common cause of bacter-
aemia in Laos and necessitates a prolonged treatment 
course of ceftazidime followed by co- trimoxazole, but 
acquired AMR has not become a clinical problem.48 
Zoonoses such as rickettsial pathogens and leptospirosis 
are common causes of febrile diseases in Laos; the limited 
evidence also suggests that acquired AMR in these infec-
tions is not yet a major issue48 49 (online supplemental 
appendix 2).
Evidence of AMR in bacteria in animals
Data on food production animal AMR in Laos are very 
limited, with the majority on Salmonella spp.,50–54 followed 
by E. coli,19 53 55 with sparser data for Enterococcus faecalis 
and Enterococcus faecium56 (online supplemental appendix 
3). The proportion of Salmonella spp. contaminating 
pork/pig carcasses, beef and buffalos at slaughterhouses 
and retail markets in central and southern Laos ranged 
from 39% to 93% from 2007 to 2017, with the proportion 
of quinolone resistance at 2%–25%.50–53 Food produc-
tion animals carrying ESBL- producing E. coli were also 
described in a remote rural village in Xiengkhuang Prov-
ince in northern Laos. Of 252 food production animal 
rectal swabs, 21 (8%) carried ESBL- producing E. coli, 
even though these food production animals were mostly 
born in the village and fed with local products.19 Four 
colistin- resistant E. coli isolates from pigs have been 
described and also identified in a Lao boy with the same 
novel ST as his family’s pigs.55
Evidence of AMU in Laos
AMU in Laos has also not been widely studied. Here we 
summarise ten AMU data sources for humans; one dataset 
and nine publications. Information on animal use is very 
limited, with only four veterinary student theses, one 
published report and one publication (online supple-
mental appendix 4).
AMU in humans
Antimicrobials were prescribed for between 45% and 
70% of inpatients in Lao hospitals from 2004 to 2018.57–60 
Doctors stated that they mainly prescribed antibiotics 
according to the National Standard Treatment Guide-
lines (STG), advice from their peers or from more expe-
rienced colleagues.57 Until recently these guidelines 
have not included detailed recommendations for anti-
microbial prescribing for the diversity of Lao infectious 
diseases, but detailed MoH antimicrobial guidelines have 
now been released.61 62
From 2017 to 2018, five hospitals (Mahosot Hospital, 
Xiengkhuang, Luang Namtha, Vientiane and Salavan 
Provincial Hospitals) participated in the Global Point 
Prevalence Survey (http://www. global- pps. com) (Chans-
amouth et al. in prep). Of 1,981 hospitals charts screened, 
1,386 (70%) patients received antimicrobial(s); the 
proportion of antimicrobial prescriptions was higher in 
provincial hospitals than in central hospitals at 72% vs 
66% (p=0.003). Of 1,386 patients prescribed antimicro-
bial(s), 596 (43%) were prescribed two or more. Of all 
prescriptions, beta- lactams accounted for 1,272/2,052 
(62%) (67% cephalosporins, 30% penicillins, 2% beta- 
lactam/beta- lactamase inhibitors and 1% carbapenems), 
metronidazole 287/2,052 (14%) and aminoglycosides 
226/2,052 (11%) (online supplemental appendix 6 and 
7).59 The appropriateness of the antimicrobials was not 
assessed. However, in Luang Namtha Provincial Hospital 
from 2008 to 2010, 560/1,095 (51%) patients received 
antibiotics but only 39/560 (7%) of these were consid-
ered appropriate.27 In an analysis of antibiotic use in 
2019, 397/413 (94%) of patients were prescribed anti-
biotics for upper respiratory infection and 8/164 (4.9%) 
for common colds. First- line antibiotics based on Lao 
National STG (amoxicillin, ampicillin, erythromycin and 
penicillin V) were the most commonly prescribed.60
A large survey in Salavan Province between 2017 and 
2018 revealed that among 796 participants from commu-
nities, 39% claimed that they used antibiotics during their 
previous illness and 22% admitted that they used anti-
biotics without indications or from informal sources.63 
‘Ampi’ or ampicillin was the most commonly mentioned 
antibiotic, by 76% of 775 survey participants, and wound 
treatment (44%) was the main reason for antibiotic use 
in Salavan in the same period.64 In Vientiane and Cham-
pasak Provinces, among 500 adults who self- medicated 
with antimicrobials for reproductive tract infections 
during the previous year, ampicillin (165 (33%)) was the 
most frequently used, and more than 50% used unrecom-
mended combined medications.65 Participants claimed 
that seeing a doctor might not be necessary because 
they could easily access antibiotics without prescriptions 
and they obtain the same antibiotic that they had used 
previously.66 Pharmacies were common sources of anti-
biotics for self- medication (85% (326/384)) in three 
districts of Vientiane City in 2017.67 Moreover, some 
participants could access antibiotics from local grocery 
shops (69/384 (18%)).67 The use of antibiotics prior to 
hospital consultation, as indicated by antibiotic activity in 
urine, was significantly higher in children (60%) than in 
adults (47%) (p<0.0001).68 Ampicillin, amoxicillin, peni-
cillin and tetracycline were frequently chosen for self- 
medication before deciding to go to hospital.31 65 68
More than one- third of Lao doctors from 25 public 
hospitals in four provinces thought that antibiotics 
in their hospitals were of poor quality.57 However, for 
consumers the cost of medications was of greater concern 
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than their quality.57 69 Indeed, issues with substandard 
and falsified antibiotics have been described in Laos and 
these are likely to be globally neglected drivers of AMR 
and impaired patient outcome.70 71
AMU in animals
The use of antibiotics in Lao livestock is thought to be 
common but is not adequately supervised and there are 
few available data.72 73 Although no antimicrobial agents 
for animals have been registered with the Lao Depart-
ment of Livestock and Fisheries (DLF), some antibiotics 
and vaccines are available at the DLF pharmacy and 
at private animal clinics. Most available publications/
reports on AMU in animals focused on targeted treat-
ment rather than growth promotion. Between 2002 and 
2017, four students (out of 872) at the Department of 
Veterinary Medicine and DLF, National University of 
Laos studied the use of antibiotics in animals. These four 
theses focused on the effects of the use of cephalexin, 
amoxicillin, clavulanate, oxytetracycline, sulphonamides, 
enrofloxacin and gentamicin for treating infections in 
domestic dogs, with no studies on livestock.74–77 Among 
domestic elephants in Xayabury Province, antibiotics were 
used for treatment of abscesses, superficial wounds and 
eye problems. Oxyblue spray or penicillin–streptomycin 
were commonly used for abscesses and enrofloxacin for 
UTIs. As the country lacks provincial veterinary diag-
nostic laboratories, most infectious disease treatments in 
animals are empirical.78 A recent article on the antibiotic 
supply chain in the animal sector in Laos, but outside this 
review period,21 found that of 96 chicken farms and 96 
pig farms, 49% and 60%, respectively, claimed that they 
gave antibiotics to their animals. Of 29 chicken farms 
with antibiotics found during the survey, tetracycline was 
the most commonly found, in 10/29 (34%) of chicken 
farms. Amoxicillin was the most common in pig farms at 
17/73 (23%).21 There have not been reports or data on 
AMU in aquaculture, nor on AMR among fish bacterial 
pathogens in Laos.
AMR pathogens in the environment
There is almost no information on contamination of the 
Lao environment with AMR pathogens. In 2003, drug- 
resistant Vibrio cholerae from surface water samples was 
sought in thirteen tributaries of the Mekong River in 
cholera- epidemic areas in Laos after an outbreak in 2000. 
Twenty- two non- O1 and non- O139 V. cholerae isolates 
were tested against polymyxin B, tetracycline, ampicillin, 
ampicillin- clavulanic acid, erythromycin, nalidixic acid, 
chloramphenicol, trimethoprim–sulfamethoxazole and 
streptomycin. Polymyxin B resistance was found in 2/22 
(9%) and ampicillin- resistance in 15/22 (68%), although 
isolates were susceptible to other tested antibiotics.79
DISCUSSION
There is little evidence on AMR awareness and how 
to engage with the public, health workers and policy 
makers in Laos.57 58 80 A large multicentre study of AMR 
awareness across 12 WHO member states (two from each 
WHO region) showed that the level of knowledge and 
awareness around appropriate antibiotic use varies from 
country to country.81 Many participants (32%–62%) 
thought that they should stop taking antibiotics when 
they felt better. Nearly half (43%) thought that they could 
buy the same antibiotics again if they had made them feel 
better during a previous illness and 44% believed that 
AMR is only a problem in people who take antibiotics 
regularly.81
Antimicrobial misuse in animal husbandry is thought 
to be one of the most important AMR drivers. However, 
we could not find any data on antibiotic use in livestock 
and aquaculture in Laos during this review period. There 
is an urgent need in Laos to systematically collect and 
analyse data on antibiotic use, consumption and resis-
tance in humans, animals and the environment. Innova-
tive public engagement strategies will be needed to raise 
awareness of optimal AMU and the risks of AMR.82
AMR data compared with adjacent countries
Data on AMR among GLASS target pathogens are not 
well documented in Laos compared with neighbouring 
countries (tables 1 and 2). Most publications investigated 
causes of fever rather than specific pathogens and their 
susceptibility patterns. In Laos, current evidence suggests 
that the main concern is an increase in ESBL- producing 
E. coli. Community- acquired and hospital- acquired bacte-
raemia have not been well distinguished and further 
work to focus on this will be important. There is evidence 
for the emergence of carbapenem- resistant E. coli and K. 
pneumoniae, and colistin- resistant K. pneumoniae in Laos. 
Carbapenems and amikacin are the only antibiotic of 
choice for ESBL treatment available in Laos. It would be 
of great concern if combined carbapenem and colistin 
resistance were to emerge (colistin is not currently avail-
able in Laos for human use) as this would lead to infec-
tions that are essentially untreatable in Laos.
MRSA is a universal public health concern, and well 
documented in neighbouring countries. In 2021, Vu et al 
reported that 3,302/4,515 (73%) of S. aureus in all spec-
imen types from 13 hospitals in Vietnam during 2016 and 
2017 were MRSA. In addition, of 674 S. aureus isolates 
from blood or CSF, 71% (476) were MRSA.83 In Thailand, 
the proportion of MRSA was high among patients with 
hospital- acquired S. aureus bacteraemia (48%, n=441), 
and 7% (n=1145) among community- acquired bacte-
raemia patients. The proportion of MRSA not suscep-
tible to vancomycin (Vancomycin- resistant Staphylococcus 
aureus (VRSA)) was 0.4% (6/1,380).84 MRSA bacteraemia 
was also common in a large bacteraemia study (n=4,833 
adult patients) in Phnom Penh, Cambodia; 22% (10/46) 
of S. aureus were MRSA but all were susceptible to vanco-
mycin.85 In contrast, in Laos only six MRSA were isolated 
from blood during this review period; the number of 
MRSA in non- blood specimens was higher (15%). VRSA 
has not yet been reported in Laos.
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These data suggest that Laos is thus surrounded by 
countries with an apparently higher frequency of antibi-
otic resistant pathogens. Paucity of AMR and AMU data 
puts Laos at a disadvantage in terms of understanding 
and controlling antibiotic resistance. However, the Lao 
data suggest that key bacterial pathogens within the 
country generally have a lower frequency of AMR than 
adjoining countries, especially S. aureus and S. Typhi, but 
that Laos has a severe and growing problem with ESBL 
production in E. coli, not only in patients but also in 
carriage by healthy individuals.17–19
Although there are no data to inform this objectively, 
Laos’ apparently lower burden of AMR may have resulted 
from historically lower antibiotic access and use due to 
Table 1 Lao antimicrobial resistance frequency for Escherichia coli, isolated from blood and cerebrospinal fluid, compared 
with equivalent data from adjacent countries
E. coli













ESBL 135/693 (19%)‡ 4,085/6,953 (59%) 655/1,107 (59%) 62 (48%)
Amikacin 2/135 (1%) 4,188/8,785 (48%) 637/1,471 (43%) 5 (4%) 130/3,408 (4%)
Gentamicin 120/675 (18%) 73 (56%) 903/4228 (21%)
Cefotaxime – 5,441/8,195 (66%) 931/1,402 (66%) 67 (52%) 885/3,892 (23%)
Ceftazidime 69/180 (38%) 47 (36%) 721/3,817 (19%)
Chloramphenicol 148/579 (26%) – – – 18/72 (25%)
Ciprofloxacin 74/231 (32%) 5,813/8,682 (67%) 953/1,475 (65%) 85 (65%) 1,120/3,836 (29%)
Co- amoxiclav 94/673 (14%) 1,476/3,251 (45%) 180/577 (31%) 64 (49%) 1,139/3,910 (29%)
Imipenem – 961/8,830 (11%) 116/1,483 (8%) – 6/3,179 (<1%)
Meropenem 0/144 (0) 0 2/2,546 (<1%)
Trimethoprim–
sulfamethoxazole
429/704 (61%) 5,704/7,843 (73%) 935/1,377 (68%) 214 (95%) 2,257/3,799 (59%)
Note that there are a paucity of published data and the year ranges differ between countries.
*LOMWRU data held by Microbiology/LOMWRU, Mahosot Hospital.
†Antimicrobial testing data from Vu et al.83 showed as a class of antibiotic rather than antibiotic agent.
‡Duration: 2004–2016; ESBL- producing E. coli in 2016 only was 27/78 (35%) in blood. However, ESBL- producing E. coli in urine (2017–2018) 
was 90/169 (53%).
CSF, cerebrospinal fluid; ESBL, extended spectrum beta lactamas; LOMWRU, Lao- Oxford- Mahosot Hospital- Wellcome Trust Research Unit.
Table 2 Lao antimicrobial resistance frequency for Staphylococcus aureus, isolated from blood and cerebrospinal fluid, 
compared with equivalent data from adjacent countries
S. aureus













MRSA † 3,302/4,515 (73%) 476/674 (71%) 10/46 (22%) 357/389 (92%)
Ciprofloxacin – 1,720/4,619 (37%) 297/689 (43%) – 7/63 (11%)
Erythromycin 70/180 (39%) 3,861/4,661 (83%) 545/639 (79%) 24/46 (52%) 436/1,785 (24%)
Gentamicin 2/166 (1%) 1,674/4,090 (41%) 294/637 (46%) – 106/719 (15%)
Penicillin 158/170 (93%) 2,347/2,400 (98%) 490/504 (97%) 45/46 (98%) –
Tetracycline 39/81 (48%) – 24/46 (52%) –
Trimethoprim–
sulfamethoxazole
16/151 (11%) 1021/4158 (25%) 233/661 (35%) 11/46 (24%) 341/1,828 (19%)
Vancomycin 0/52 (0) 45/2,680 (2%)‡ 7/565 (1%) – 6/1,380 (<1%)
Note that there are a paucity of published data and the year ranges differ between countries.
*Antimicrobial testing data from Vu et al83 showed as a class of antibiotic rather than antibiotic agent.
†The first MRSA bacteraemia in Laos was identified in 2017.
‡Resistant and intermediate.
CSF, cerebrospinal fluid; MRSA, methicillin- resistant Staphylococcus aureus.
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being relatively isolated until ~20 years ago and financially 
impoverished, and there being only a small accessible 
commercial antibiotic market in the past. However, the 
apparent lower AMR burden may also partly reflect the 
paucity of systematic surveillance and research. Recent 
initiatives such as support for AMR and AMU surveillance 
by MoH through the Fleming Fund86 and KOICA87 aim 
to increase the availability of actionable data from across 
the country. Related initiatives such as the development 
of updated MoH infectious diseases treatment guidelines, 
AMR and AMU dashboards (https://www. youtube. com/ 
watch? v= QELwHIPsKw4) will facilitate policy engagement 
and enhance antibiotic stewardship and AMR prevention, 
detection and pharmacist- led antimicrobial stewardship 
programmes and empowering hospital drugs and ther-
apeutics committees could be explored as interventions 
to enhance AMU within healthcare facilities. Although it 
is illegal to sell antibiotics without a prescription in Laos, 
buying antibiotics without a prescription is anecdotally 
common and interventions to improve this situation will 
be vital. Recent interventions such as detailed antimicro-
bial treatment guidelines and inpatient and outpatient 
patient AMU data collection will provide an infrastruc-
ture for improving and monitoring AMU.
Limitations
Data on AMU and AMR in Laos are sparse and scattered 
and are mostly from Vientiane City. The majority (49%) 
of data sources on AMR and AMU were from one site, 
at LOMWRU/ Mahosot Hospital. Though the number 
of publications on infectious diseases in Laos has greatly 
increased since 2000,47 88 there are few articles that specif-
ically describe the AMU and AMR situations in Laos. 
Fifteen percent of the data sources on AMR and AMU in 
this review were not peer- reviewed. The majority of data 
were from epidemiological studies, cross- sectional studies 
and three large microbiology datasets from LOMWRU/
Mahosot Hospital from 2000 to 2020.
CONCLUSION
If AMR is, as these data suggest, of relatively low frequency 
in Laos for some GLASS target pathogens, it gives the 
country a key window of opportunity to act quickly to 
implement strategies to protect the population and health 
system from a worsening situation, through preventing, 
detecting and responding to AMR threats. However, the 
paucity of systematic surveillance of AMR and AMU in 
Laos must be taken into account when interpreting the 
low frequency of AMR in this setting. Enhanced coordi-
nated and systematic AMU and AMR surveillance across 
the country is needed. Laos needs enhanced regulation 
of antibiotic availability, without compromising appro-
priate access, and strengthened antibiotic stewardship in 
health facilities and the community for systematic control 
and rationalisation of AMU, in order to prevent resist-
ance before it spreads and becomes harder to manage. 
Strategies should also be put in place to control the use of 
colistin in livestock, as colistin is currently a last resort for 
treating key drug resistant pathogens. Specific strategies 
should also be developed to prevent a rise in S. aureus and 
S. Typhi resistance to key antibiotics and to reduce the 
high prevalence of ESBL- producing Enterobacterales.
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